This episode explores the growing role of antibody–drug conjugates (ADCs) in the treatment of ovarian cancer. ADCs combine a targeted monoclonal antibody with a cytotoxic drug, allowing chemotherapy to be delivered directly to tumor cells while limiting damage to healthy tissue.

The discussion highlights two currently approved ADCs in ovarian cancer: mirvetuximab soravtansine, used for platinum-resistant disease with high folate receptor alpha (FRα) expression, and trastuzumab deruxtecan, used for tumors with HER2 overexpression. Key clinical evidence is reviewed, particularly the MIRASOL phase 3 trial, which showed improved progression-free survival, response rate, and overall survival with mirvetuximab compared with chemotherapy.

The episode also discusses emerging research, including combination strategies such as mirvetuximab with ...